Literature DB >> 3036946

Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein.

R J Robb, R M Kutny.   

Abstract

The Tac protein is one of at least two glycoproteins known to bind the growth and differentiation factor interleukin 2 (IL 2). In addition to its location on the cell surface, where it plays a part in high and low affinity IL 2 receptors, Tac is released from activated lymphocytes in a soluble form. We observed this release both for Tac protein labeled biosynthetically and for Tac protein labeled by surface iodination of intact cells. Competitive binding studies indicated that the soluble Tac protein retained an ability to bind IL 2 with a low affinity (Kd of 11.1 nM). In addition, structural analysis revealed that the polypeptide chain began at position 1 and ended at or just before Cys-192 of the full-length molecule. Thus, the protein was missing its normal transmembrane and intracytoplasmic segments, accounting for its solubility and cellular release. The apparent lack of modification in the amino acid sequence and the termination at Cys-192 are inconsistent with a mechanism of cellular release dependent only on alternate mRNA splicing. Instead, the results suggest that proteolysis may accompany the release of soluble Tac protein from cells expressing IL 2 receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036946

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.

Authors:  Satoshi Nagata; Tomoko Ise; Masanori Onda; Kazuyasu Nakamura; Mitchell Ho; Andrew Raubitschek; Ira H Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-19       Impact factor: 11.205

2.  Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism.

Authors:  S Horiuchi; Y Koyanagi; Y Tanaka; M Waki; A Matsumoto; Y W Zhou; M Yamamoto; N Yamamoto
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

3.  C-terminal truncated forms of Met, the hepatocyte growth factor receptor.

Authors:  M Prat; T Crepaldi; L Gandino; S Giordano; P Longati; P Comoglio
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

4.  Spontaneous solubilization of membrane-bound human testis angiotensin-converting enzyme expressed in Chinese hamster ovary cells.

Authors:  M R Ehlers; Y N Chen; J F Riordan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

5.  Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Authors:  Remi M M Vanmaris; Ger T Rijkers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

6.  Expression of functional interleukin 2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis.

Authors:  Z Toossi; J R Sedor; J P Lapurga; R J Ondash; J J Ellner
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

7.  Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  M Itoh; Y Goto; Y Ohta; Y Goto; H Ohashi
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 8.  Membrane protein secretases.

Authors:  N M Hooper; E H Karran; A J Turner
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

9.  Optimization of the cytokine secretion assay for human IL-2 in single and combination assays.

Authors:  Nan Deng; Tim R Mosmann
Journal:  Cytometry A       Date:  2015-04-28       Impact factor: 4.355

10.  CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.

Authors:  G C de Gast; I A Haagen; A A van Houten; S C Klein; A J Duits; R A de Weger; T M Vroom; M R Clark; J Phillips; A J van Dijk
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.